Richard T. Kloos, MD joined Veracyte in 2012 as the Senior Medical Director of Endocrinology. Prior to joining Veracyte, Dr. Kloos was a Professor in the Divisions of Endocrinology and Metabolism, and Nuclear Medicine at The Ohio State University (OSU), the Arthur G. James Cancer Hospital/Richard J. Solove Research Institute, and the OSU Comprehensive Cancer Center in Columbus, Ohio. Dr Kloos was also co-director of The OSU Thyroid Cancer Unit. Dr. Kloos achieved board certification in both nuclear medicine and internal medicine, and subspecialty certification in endocrinology, diabetes, and metabolism. He is a member and past Secretary/Chief Operating Officer for the American Thyroid Association (ATA), and an active member of the Endocrine Society, the American Association of Clinical Endocrinologists (AACE), the Latin American Thyroid Society (LATS) and the European Thyroid Association (ETA).
Dr. Kloos contributed to several guidelines efforts including: member of the National Comprehensive Cancer Network (NCCN) guidelines committee for thyroid carcinoma from 1998-2012, task force member for the ATA thyroid nodules and differentiated thyroid cancer guidelines (2006 and 2009 publications), and was chairman of the ATA guidelines for medullary thyroid cancer published in 2008. Dr. Kloos is an author of more than 100 peer-reviewed journal articles and book chapters, an ad-hoc reviewer for multiple journals, and a past-member of the Editorial Board for the Journal of Clinical Endocrinology & Metabolism.
A graduate of the University of Chicago with honors, Dr. Kloos received his medical degree from Case Western Reserve University School of Medicine and completed his internal medicine internship and residency at MetroHealth Medical Center in Cleveland, Ohio. His postdoctoral training continued at the University of Michigan, Ann Arbor, first in the Division of Endocrinology and Metabolism, and then in the Division of Nuclear Medicine.